Autoantibody

Antibody Testing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Products, Indication, End User - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 26, 2022 - 4:33pm

The "Antibody Testing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Products, Indication , End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Antibody Testing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Products, Indication , End User" report has been added to ResearchAndMarkets.com's offering.
  • However, the antibody testing market is likely to get impacted by the limitations of antibody screening tests during the forecast period.
  • Additionally, growing government support is fueling the growth of antibody testing, which influences the development of the global antibody testing market.
  • In long run antibody testing market would have significant growth prospects as many market players have received emergency use authorization for their newly developed antibody tests.

Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress

Retrieved on: 
Friday, May 20, 2022 - 9:05pm

These data were included in two oral presentations at the European Renal Association - European Dialysis Transplant Association (ERA-EDTA) Congress being held May 19-22, 2022 in Paris, France, in person and virtually.

Key Points: 
  • These data were included in two oral presentations at the European Renal Association - European Dialysis Transplant Association (ERA-EDTA) Congress being held May 19-22, 2022 in Paris, France, in person and virtually.
  • Dr. Lin continued, We also presented new data from a post-hoc analysis from our double-blind, placebo-controlled Phase 2 study which suggested atacicept has the potential to improve renal function in patients with mild-to-moderate SLE renal disease.
  • We anticipate the planned Phase 3 COMPASS clinical trial evaluating atacicept 150 mg to help determine whether atacicept improves renal function in moderate-to-severe lupus nephritis.
  • Results from this post-hoc analysis of the Phase 2 trial of atacicept in SLE suggest atacicept may improve renal function in patients with mild-to-moderate SLE renal disease.

Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 16, 2022 - 12:30pm

Topline results from the study are expected to be presented in the fourth quarter 2022, which we expect will be used to support the initiation of a pivotal Phase 3 clinical trial of atacicept in 2023.

Key Points: 
  • Topline results from the study are expected to be presented in the fourth quarter 2022, which we expect will be used to support the initiation of a pivotal Phase 3 clinical trial of atacicept in 2023.
  • Enrollment in the Phase 2b ORIGIN clinical trial of atacicept remains on track, topline data expected in the fourth quarter 2022.
  • Vera reported approximately $151 million in cash, cash equivalents and marketable securities as of March 31, 2022.
  • Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases.

Calliditas Therapeutics Launches an Online Patient Platform

Retrieved on: 
Saturday, May 14, 2022 - 1:00pm

STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.

Key Points: 
  • STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.
  • Bonnie Schneider, Director and Co-Founder of the IgA Nephropathy Foundation of America commented, IgA nephropathy is a complicated disease that can leave individuals with many unanswered questions.
  • With the launch of IgAN Connect, I am grateful that individuals will have even more resources to embark on this journey.
  • Calliditas common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).

Horizon Therapeutics plc Launches Letter-Writing Campaign to Empower Those Living with Thyroid Eye Disease (TED) to Confront the Condition Head On

Retrieved on: 
Wednesday, May 11, 2022 - 1:30pm

Living with a rare or chronic disease is a very personal experience that can sometimes feel isolating and overwhelming, said Gottlieb.

Key Points: 
  • Living with a rare or chronic disease is a very personal experience that can sometimes feel isolating and overwhelming, said Gottlieb.
  • My relationship with TED hasnt been easy, but because of what Ive been through, I take pride in everything Ive accomplished.
  • It is important to monitor eye symptoms and take weekly pictures to capture any changes in appearance.
  • Cockerham K, Stuertz N, Padnick-Silver L. Quality of Life Assessment of Chronic Thyroid Eye Disease (TED) Patients in the United States.

Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy

Retrieved on: 
Monday, May 9, 2022 - 1:00pm

IRVINE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today reported that the first patient has been dosed in a Phase 2a study evaluating tegoprubart in patients with IgA Nephropathy (IgAN).

Key Points: 
  • IRVINE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today reported that the first patient has been dosed in a Phase 2a study evaluating tegoprubart in patients with IgA Nephropathy (IgAN).
  • "We are pleased to begin our clinical evaluation of tegoprubart in this area of great unmet need and look forward to sharing early results from this Phase 2a study at the end of the year."
  • Eledon is headquartered in Irvine, Calif. For more information, please visit the company's website at www.eledon.com .
  • Follow Eledon Pharmaceuticals on social media: LinkedIn ; Twitter
    This press release contains forward-looking statements that involve substantial risks and uncertainties.

Vera Therapeutics to Present at Upcoming Conferences in May 2022

Retrieved on: 
Thursday, May 5, 2022 - 9:05pm

A replay of the event will be available for 30 days and can be accessed by visiting the Investor Calendar section of the Vera Therapeutics website.

Key Points: 
  • A replay of the event will be available for 30 days and can be accessed by visiting the Investor Calendar section of the Vera Therapeutics website.
  • Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases.
  • Veras mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients.
  • In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful.

Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia

Retrieved on: 
Thursday, May 5, 2022 - 4:54pm

SHANGHAI, China and SAN FRANCISCO and CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the company’s partner argenx (Euronext & Nasdaq: ARGX) reported positive data from the Phase 3 ADVANCE trial of VYVGART® (efgartigimod alfa-fcab).

Key Points: 
  • In adults with primary ITP, ADVANCE met its primary endpoint demonstrating that a higher proportion of chronic ITP patients receiving VYVGART achieved a sustained platelet count response compared to placebo.
  • ADVANCE is the first Phase 3 clinical trial of a neonatal Fc receptor (FcRn) blocker in ITP.
  • Additional secondary endpoint data from the ADVANCE trial are consistent with primary and secondary platelet-derived endpoints and provide additional context on metrics that often drive treatment decisions.
  • The Phase 3 ADVANCE trial was a randomized, double-blind, placebo-controlled, multicenter, global trial evaluating the efficacy and safety of VYVGART in adult patients with chronic or persistent primary ITP.

Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus

Retrieved on: 
Tuesday, May 3, 2022 - 9:33pm

These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases, including IgA nephropathy (IgAN) and lupus nephritis.

Key Points: 
  • These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases, including IgA nephropathy (IgAN) and lupus nephritis.
  • Atacicept showed a dose-dependent effect on key biomarkers and clinical markers in a Phase 2a clinical study in patients with IgAN.
  • Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases.
  • In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful.

Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022

Retrieved on: 
Tuesday, May 3, 2022 - 12:06am

MAU868 is currently undergoing a randomized, double-blind, placebo-controlled Phase 2 clinical trial to assess the safety, pharmacokinetics, and efficacy for the treatment of BKV in kidney transplant patients.

Key Points: 
  • MAU868 is currently undergoing a randomized, double-blind, placebo-controlled Phase 2 clinical trial to assess the safety, pharmacokinetics, and efficacy for the treatment of BKV in kidney transplant patients.
  • Veras mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients.
  • In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful.
  • Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplant.